Inefficacy of the association N-methyl glucamine and topical miltefosine in the treatment of experimental cutaneous leishmaniasis by Leishmania (Leishmania) amazonensis

被引：0

作者：

Sampaio, R. N. R. ^{[1
]}

Lucas, I. C. ^{[1
]}

Takami, H. L. ^{[1
]}

机构：

[1] Univ Brasilia, Lab Dermatomycol, BR-70910900 Brasilia, DF, Brazil

来源：

JOURNAL OF VENOMOUS ANIMALS AND TOXINS INCLUDING TROPICAL DISEASES | 2007年 / 13卷 / 03期

关键词：

Cutaneous leishmaniasis; miltefosine; N-methyl glucamine; ORAL MILTEFOSINE; HEXADECYLPHOSPHOCHOLINE; TRIAL; CHEMOTHERAPY; INFECTION;

D O I：

暂无

中图分类号：

R99 [毒物学（毒理学）];

学科分类号：

100405 ;

摘要：

Pentavalent antimonial (Sb-V) is the first treatment for cutaneous leishmaniasis (CL). Other drugs present similar side effects and higher cost. Oral miltefosine is effective to treat kala-azar. The aim of the present study was to compare the efficacy of glucamine ( SbV) plus topical miltefosine with glucamine in the treatment of CL. Eighty isogenic C57BL/6 mice were inoculated with Leishmania (Leishmania) amazonensis and divided into two groups: one group was treated with SbV associated with miltefosine, and the other group received SbV plus saline solution. Groups were evaluated according to the diameter of the inoculated foot pad, the culture, and the parasite count using the limiting dilution assay. There was not statistical difference. The efficacy of glucamine in CL treatment did not increase when associated with topical miltefosine.

引用

页码：598 / 606

页数：9

共 26 条

[1] AN EXPERIMENTAL-MODEL SYSTEM FOR LEISHMANIASIS - AN ULTRASTRUCTURAL-STUDY ON CULTURED MACROPHAGES EXPOSED TO LEISHMANIA PARASITES AND SODIUM STIBOGLUCONATE
ABOK, K
FREDRIKSSON, BA
BRUNK, U
[J]. APMIS, 1988, 96 (07) : 589 - 595
[2] Human leishmaniasis: Clinical, diagnostic, and chemotherapeutic developments in the last 10 years
Berman, JD
[J]. CLINICAL INFECTIOUS DISEASES, 1997, 24 (04) : 684 - 703
[3] Deps P D, 2000, Rev Soc Bras Med Trop, V33, P535, DOI 10.1590/S0037-86822000000600004
[4] DRUG-RESISTANCE IN LEISHMANIASIS - ITS IMPLICATION IN SYSTEMIC CHEMOTHERAPY OF CUTANEOUS AND MUCOCUTANEOUS DISEASE
GROGL, M
THOMASON, TN
FRANKE, ED
[J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1992, 47 (01) : 117 - 126
[5] Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis
Jha, TK
Sundar, S
Thakur, CP
Bachmann, P
Karbwang, J
Fischer, C
Voss, A
Berman, J
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (24) : 1795 - 1800
[6] KUBLENCORD A, 1992, ANTIMICROB AGENTS CH, V36, P1630
[7] Short- and long-term efficacy of hexadecylphosphocholine against established Leishmania infantum infection in BALB/c mice
Le Fichoux, Y
Rousseau, D
Ferrua, B
Ruette, S
Lelièvre, A
Grousson, D
Kubar, J
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (03) : 654 - 658
[8] Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer
Leonard, R
Hardy, J
van Tienhoven, G
Houston, S
Simmonds, P
David, M
Mansi, J
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (21) : 4150 - 4159
[9] Ether-lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether-lipid analogues in Leishmania
Lux, H
Heise, N
Klenner, T
Hart, D
Opperdoes, FR
[J]. MOLECULAR AND BIOCHEMICAL PARASITOLOGY, 2000, 111 (01) : 1 - 14
[10] Marsden P D, 1994, Rev Soc Bras Med Trop, V27, P93, DOI 10.1590/S0037-86821994000200007

← 1 2 3 →